{
    "Overall_score": {
        "Correlation": 7,
        "Sentiment": 5,
        "Importance": 6,
        "Impact": 6,
        "Duration": 4,
        "Virality": 3,
        "Source_Score": 8,
        "Specificity": 7,
        "Sector_Spread": 5,
        "Tech_Mentions": 2
    },
    "Each_item": [
        {
            "News_content": "Penn's FitzGerald: NSAIDs will confer a risk of hypertension that will relate to the degree of selectivity for COX-2",
            "Correlation": 6,
            "Sentiment": 4,
            "Importance": 5,
            "Impact": 5,
            "Duration": 3,
            "Virality": 2,
            "Source_Score": 8,
            "Specificity": 7,
            "Sector_Spread": 4,
            "Tech_Mentions": 1
        },
        {
            "News_content": "UPenn's Garrett FitzGerald says PFE's PRECISION trial evaluating safety of Celebrex v. ibuprofen v. naproxen is biased",
            "Correlation": 7,
            "Sentiment": 6,
            "Importance": 7,
            "Impact": 6,
            "Duration": 4,
            "Virality": 3,
            "Source_Score": 8,
            "Specificity": 8,
            "Sector_Spread": 5,
            "Tech_Mentions": 2
        },
        {
            "News_content": "Important data coming out: Athersys nears end Ph2 in IBD. Partnered with PFE",
            "Correlation": 8,
            "Sentiment": 7,
            "Importance": 8,
            "Impact": 7,
            "Duration": 5,
            "Virality": 4,
            "Source_Score": 7,
            "Specificity": 9,
            "Sector_Spread": 6,
            "Tech_Mentions": 3
        }
    ]
}